(A) Combination of the original and validation cohort showing subtype, score, MYC/TP63 gene expression levels, tumor stage, histology, and primary site. *p<0.05 association with subtype.
(B) Overall survival in combined cohort. Log-rank test.
(C) Multivariate survival analysis using Cox proportional hazards model in the combined cohort accounting for subtype, tumor stage, and tumor histology.
(D) ACC-I is characterized by MYC hyperactivation via Notch or direct amplification, both of which can suppress p63. In absence of these events, p63 drives EGFR or other RTKs to promote proliferation.